Royal Bank of Canada
ADPT icon

Royal Bank of Canada’s Adaptive Biotechnologies ADPT Stock Holding History

Royal Bank of Canada’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$645K Sell
46,470
-32,205
-41% -$513K ﹤0.01% 3932
2025
Q4 		$1.28M Sell
78,675
-22,582
-22% -$369K ﹤0.01% 3473
2025
Q3 		$1.51M Sell
101,257
-378,525
-79% -$4.61M ﹤0.01% 3629
2025
Q2 		$5.59M Buy
479,782
+466,302
+3,459% +$4.24M ﹤0.01% 2479
2025
Q1 		$100K Sell
13,480
-1,375
-9% -$10.6K ﹤0.01% 5214
2024
Q4 		$88K Buy
14,855
+3,139
+27% +$17.3K ﹤0.01% 5404
2024
Q3 		$60K Buy
11,716
+472
+4% +$2.06K ﹤0.01% 5608
2024
Q2 		$40K Buy
11,244
+7,402
+193% +$23.5K ﹤0.01% 5749
2024
Q1 		$12K Sell
3,842
-30,643
-89% -$119K ﹤0.01% 6120
2023
Q4 		$169K Buy
34,485
+32,115
+1,355% +$147K ﹤0.01% 5243
2023
Q3 		$13K Sell
2,370
-12,319
-84% -$81.5K ﹤0.01% 6329
2023
Q2 		$98K Buy
14,689
+5,646
+62% +$42K ﹤0.01% 5356
2023
Q1 		$80K Sell
9,043
-12,345
-58% -$109K ﹤0.01% 5342
2022
Q4 		$163K Buy
21,388
+16,021
+299% +$125K ﹤0.01% 5052
2022
Q3 		$38K Buy
5,367
+250
+5% +$2.35K ﹤0.01% 5869
2022
Q2 		$41K Sell
5,117
-2,900
-36% -$25.5K ﹤0.01% 5803
2022
Q1 		$111K Buy
8,017
+2,885
+56% +$45.4K ﹤0.01% 5572
2021
Q4 		$144K Sell
5,132
-730
-12% -$22.4K ﹤0.01% 5657
2021
Q3 		$199K Sell
5,862
-350
-6% -$12.7K ﹤0.01% 5176
2021
Q2 		$254K Sell
6,212
-8,946
-59% -$348K ﹤0.01% 4865
2021
Q1 		$611K Buy
15,158
+13,731
+962% +$743K ﹤0.01% 4006
2020
Q4 		$84K Buy
1,427
+613
+75% +$31.6K ﹤0.01% 5426
2020
Q3 		$40K Sell
814
-60,189
-99% -$2.53M ﹤0.01% 5432
2020
Q2 		$2.95M Sell
61,003
-1,679
-3% -$61.2K ﹤0.01% 2326
2020
Q1 		$1.74M Buy
62,682
+59,889
+2,144% +$1.67M ﹤0.01% 2594
2019
Q4 		$84K Sell
2,793
-8,386
-75% -$241K ﹤0.01% 5177
2019
Q3 		$344K Buy
11,179
+5,124
+85% +$209K ﹤0.01% 4079
2019
Q2 		$293K Buy
+6,055
New +$268K ﹤0.01% 4223

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada's ADPT Position: Q1 2026 in Review

Royal Bank of Canada reduced its Adaptive Biotechnologies (ADPT) stake by 41% in Q1 2026, selling an estimated $513K and leaving 46,470 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #3932.

Royal Bank of Canada first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $5.59M in Q2 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Royal Bank of Canada held 46,470 shares of Adaptive Biotechnologies worth $645K as of Q1 2026.
  • Royal Bank of Canada sold 32,205 Adaptive Biotechnologies shares in Q1 2026, an estimated $513K.
  • Adaptive Biotechnologies made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3932 holding.
  • Royal Bank of Canada first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • Royal Bank of Canada's Adaptive Biotechnologies position peaked at $5.59M in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.